ReviewExperimental gerontology2013
25 years after age-1: genes, interventions and the revolution in aging research.
Review in Experimental gerontology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Suppressing APOE4-induced neural pathologies by targeting the VHL-HIF axis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Suppressing APOE4-induced mortality and cellular damage by targeting VHL.bioRxiv : the preprint server for biology · 2024Article
- Genetic factors in methylmercury-induced neurotoxicity: What have we learned fromAdvances in neurotoxicology · 2023Article
- Physiological Systems in Promoting Frailty.Comprehensive Physiology · 2022Review
- Differential Dose- and Tissue-Dependent Effects of foxo on Aging, Metabolic and Proteostatic Pathways.Cells · 2021Article
- Career Retrospective: Tom Johnson-Genetics, Genomics, Stress, Stochastic Variation, and Aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- Drugs that target aging: how do we discover them?Expert opinion on drug discovery · 2019Review
- Review
- Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis.The Journal of clinical investigation · 2017Review
- Article
- Aging and Lung Disease. Clinical Impact and Cellular and Molecular Pathways.Annals of the American Thoracic Society · 2015Review
- Article
- Medical research: treat ageing.Nature · 2014Article
- Healthy aging: what can we learn from Caenorhabditis elegans?Zeitschrift fur Gerontologie und Geriatrie · 2013Review
- mTOR Inhibition: From Aging to Autism and Beyond.Scientifica · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
This communication will briefly review more than 30 years of research on aging using the nematode Caenorhabditis elegans ("The Worm") as carried out in the labs of Tom Johnson. We will highlight research directions initiated in the 1980's, which were exciting for those of us trying to turn over a new leaf in aging research. In this narrative, I will discuss primarily the science that I and my lab have been involved with for the last 30 years. This area has been fascinating to those studying the sociology of science as modern aging research has moved to replace the simplistic, poorly controlled and outright fictitious approaches seen in much of the previous aging research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.